CorMedix Therapeutics — Third Quarter 2026 Earnings Summary

CorMedix Therapeutics reported third-quarter 2026 consolidated revenue of $54.5 million and a net loss of $14.7 million, resulting in adjusted EBITDA of $3.1 million. The company announced a definitive agreement to acquire substantially all assets of Heron Therapeutics, a transaction expected to close in the first quarter of 2027 and contribute between $125 million and $150 million in revenue for the full year 2027. DefenCath sales declined to $17.2 million due to post-TDAPA pricing pressures, while the remainder of the portfolio generated $37.3 million in revenue. CorMedix maintained its full-year 2026 revenue guidance of $325 million to $345 million but narrowed its adjusted EBITDA guidance to $130 million to $140 million, while suspending 2027 DefenCath revenue guidance pending further clarity on CMS reimbursement frameworks.